PT - JOURNAL ARTICLE AU - Verma, Anurag AU - Tsao, Noah AU - Thomann, Lauren AU - Ho, Yuk-Lam AU - Iyengar, Sudha AU - Luoh, Shiuh-Wen AU - Carr, Rotonya AU - Crawford, Dana AU - Efird, Jimmy T. AU - Huffman, Jennifer AU - Hung, Adriana AU - Ivey, Kerry AU - Levin, Michael AU - Lynch, Julie AU - Natarajan, Pradeep AU - Pyarajan, Saiju AU - Bick, Alexander AU - Costa, Lauren AU - Genovese, Giulio AU - Hauger, Richard AU - Madduri, Ravi AU - Pathak, Gita AU - Polimanti, Renato AU - Voight, Benjamin AU - Vujkovic, Marijana AU - Zekavat, Maryam AU - Zhao, Hongyu AU - Ritchie, Marylyn D AU - , AU - Chang, Kyong-Mi AU - Cho, Kelly AU - Casas, Juan P. AU - Tsao, Philip S. AU - Gaziano, J. Michael AU - O’Donnell, Christopher AU - Damrauer, Scott AU - Liao, Katherine TI - A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program AID - 10.1101/2021.05.18.21257396 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.18.21257396 4099 - http://medrxiv.org/content/early/2021/10/15/2021.05.18.21257396.short 4100 - http://medrxiv.org/content/early/2021/10/15/2021.05.18.21257396.full AB - The study aims to determine the shared genetic architecture between COVID-19 severity with existing medical conditions using electronic health record (EHR) data. We conducted a Phenome-Wide Association Study (PheWAS) of genetic variants associated with critical illness (n=35) or hospitalization (n=42) due to severe COVID-19 using genome-wide association summary from the Host Genetics Initiative. PheWAS analysis was performed using genotype-phenotype data from the Veterans Affairs Million Veteran Program (MVP). Phenotypes were defined by International Classification of Diseases (ICD) codes mapped to clinically relevant groups using published PheWAS methods. Among 658,582 Veterans, variants associated with severe COVID-19 were tested for association across 1,559 phenotypes. Variants at the ABO locus (rs495828, rs505922) associated with the largest number of phenotypes (nrs495828= 53 and nrs505922=59); strongest association with venous embolism, odds ratio (ORrs495828 1.33 (p=1.32 × 10−199), and thrombosis ORrs505922 1.33, p=2.2 ×10−265. Among 67 respiratory conditions tested, 11 had significant associations including MUC5B locus (rs35705950) with increased risk of idiopathic fibrosing alveolitis OR 2.83, p=4.12 × 10−191; CRHR1 (rs61667602) associated with reduced risk of pulmonary fibrosis, OR 0.84, p=2.26× 10−12. The TYK2 locus (rs11085727) associated with reduced risk for autoimmune conditions, e.g., psoriasis OR 0.88, p=6.48 ×10−23, lupus OR 0.84, p=3.97 × 10−06. PheWAS stratified by genetic ancestry demonstrated differences in genotype-phenotype associations across ancestry. LMNA (rs581342) associated with neutropenia OR 1.29 p=4.1 × 10−13 among Veterans of African ancestry but not European. Overall, we observed a shared genetic architecture between COVID-19 severity and conditions related to underlying risk factors for severe and poor COVID-19 outcomes. Differing associations between genotype-phenotype across ancestries may inform heterogenous outcomes observed with COVID-19. Divergent associations between risk for severe COVID-19 with autoimmune inflammatory conditions both respiratory and non-respiratory highlights the shared pathways and fine balance of immune host response and autoimmunity and caution required when considering treatment targets.Competing Interest StatementRMC has received research support from Intercept Pharmaceuticals, Inc and Merck & Co. MDR is on the scientific advisory board for Goldfinch Bio and Cipherome. CJO is an employee of Novartis Institute for Biomedical Research. PN reports grant support from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Genentech, and Novartis, and spousal employment at Vertex, all unrelated to the present work.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award MVP035. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. R.M.C. is supported by NIH grants R01 AA026302 and P30 DK0503060. K.P.L. is supported by NIH P30 AR072577, and the Harold and Duval Bowen Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award MVP035. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull summary-level association data from the PheWAS from this study is made available as supplementary files.